Does TRT Induce Prostate Cancer?
|
|
- Millicent Morrison
- 5 years ago
- Views:
Transcription
1 Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands
2 Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there an association between T level and PCA-risk? What is the risk of PCa during TRT?
3 Medical literature reviewed Guidelines: Endocrine Society, 2010 ISSM Standard Committee, 2013 ISA,ISSAM,EAU,ASA, 2010 EAU, 2012 Update on TRT, Corona G, 2011 JSM Fernandez-Balsells,2010 JCEM Khera,2013 Sex Med Rev Shared opinions/slides of Frans Debruyne and Marco Marcelli
4 Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there an association between T level and PCA-risk? What is the risk of PCA during TRT?
5 It is in our Minds!! The prostate increases in size after the onset of puberty as testosterone levels increase. without androgen the prostate regresses (lack of a palpable prostate gland in 26 eunuchs Chinese men years post-castration) Chinese Med J. 1987;100: , does not increase in size in genetic males who have complete androgen insensitivity (Corbetta S, et al. Fertil Steril. 2011;95:1119) remains rudimentary in males with 5- reductase deficiency, indicating that DHT is the major androgen in the prostate (Imperato-McGinley J, et al. J Clin Endocrinol Metab. 1992; 75:1022-6) Increases in size in men with hypogonadism after implementation of TRT Androgen depletion has been the first line of treatment for invasive PCa since 1941
6 Prostate Volume in 16 Hypogonadal Men before and after Testosterone Treatment for 36 months Snyder PJ, et al. J Clin Endocrinol Metab 2000; 85:2670 P = 0.004
7
8
9 Consequences of Huggins paper Androgen ablation became the first line of treatment for advanced prostate cancer Because prostate cancer flare up was associated with TRT, we are still questioning whether the population of patients receiving TRT is at increased risk to develop prostate cancer
10 Huggins s heritage from a 1967 review article: Orchiectomy or the administration of estrogens resulted in regression of PCa whereas, in untreated prostates,testosterone enhanced the rate of growth of cancer Huggins, Cancer Res 27 ; , 1967
11 There is general agreement that castration causes regression of PCa But There is no prove for the second part of Huggins assertion: T causes PCa to grow!! based on only one patient
12 Why is the relationship between T and PCa further under great scrutiny? TRT for hypogonadism is progressivily expanding More PCa survivors with LOH ask for TRT
13 Why is TRT a controversial topic? Is there a risk of Developing Lower Urinary Tract Symptoms(LUTS) with TRT?
14 Can TRT lead up to: Increase in prostate volume? Increased risk of LUTS and BPH? Increase in PSA levels? Stimulate growth of an occult tumor?
15 We cannot answer these questions because: 1) to establish a link between development of a disease and certain steroid hormone levels, studies need to be prospective and should last until the disease of interest has developed; 2) circulating hormone levels vary significantly throughout the day and over the years. It is difficult to determine to what extent the level of a hormone measured once, reflects a lifetime index of hormone status; 3) the levels of circulating steroid hormones do not necessarily reflect their intraprostatic concentrations.
16 Prostate Volume in 16 Hypogonadal Men before and after Testosterone Treatment for 36 months Snyder PJ, et al. J Clin Endocrinol Metab 2000; 85:2670 P = 0.004
17 AUA Symptom Index Changes During Study Period Pearl JA et al. J Urol. 2013;190: n=120; Mean duration of followup therapy:692 +/- 773 days
18 No difference in the risk of significant increase of PSA, changes in IPSS, LUTS and composite endpoints (Fernandez-Balsells, J Clin Endocrinol Metab 95: , 2010) Conclusions: these data do not support causality between Pca,LUTS and TRT
19 Does TRT induce prostate diseases? No evidence based on available data. However for conclusive evidence adequately powered prospective studies are needed Endocrine Society Guidelines: A patient on TRT needs urological consultation if there is: PSA concentration >1.4 ng/ml in a year PSA velocity of >0.4 ng/ml yr using the PSA level after6 months TRT Abnormal RT An AUA/ IPSS prostate symptom score of >19 Bhasin S, J Clin Endocrinol Metab, June 2010, 95(6):
20 Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there an association between T level and PCA-risk? What is the risk of PCA during TRT?
21 Relevant questions: It is commonly believed that PCa is an androgendependent cancer; but in that case: 1. Do high T levels contribute to the development of PCa? 2. Does high T cause rapid growth of PCa? 3. Is low T protective against development of PCa and causes it PCa to regress?
22
23 Low T is not protective while high T is not a risk factor for the development of Pca Morgentaler A, Roden EL. Urol 2006; 68:1263
24 Incidence and death rates per 100,000, US Incidence and death rates per 100,000 population prostate cancer United States, 2005 to ,7 CA Cancer J Clin ,2 98,8 124,9 Incidence Deat rate 50 53,1 21, ,7 17,8 0 White African American Asian American American Indian Hispanic
25 ng/ml Serum testosterone levels do not differ between black and white men in a nationally representative sample of Americans (NHANES III) J Clin Endocrinol Metab 92: , ,1 5, NHW 0,101 0,104 NHB Testosterone (ng/ml) Free Testosterone (ng/ml)
26 Testosterone Concentration (ng/ml) Prostate Cancer Grade: Serum Testosterone at Diagnosis Schatzl G, et al. Prostate. 2001;47:52 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 4,3 4,1 3,7 P< * n=34 n=33 n=51 n=38 Gleason Score Gleason 5 Gleason=6 Gleason=7 Gleason 8 N=156
27 Serum concentrations of sex hormones are not associated with the risk of prostate cancer J Natl Cancer Inst 2008;100: Paper by Roddam 3886 men with incident prostate cancer and 6438 controls
28 Androgen levels and PCA What learns the literature: - 18 prospective studies: 3,886 men with PCA 6,438 controls Conclusion: no association between risk of PCA and T level Roddam,2008
29 Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there an association between T level and PCA-risk? What is the risk of PCA during TRT?
30 Testosteron and risk for PCA -No correlation between higher T and PCA risk -But the opposite seems more frequently: a low T is associated with a higher PCA-risk! Selph and Carson JSex Med 2013 Garcia-Gruz 2012 Porcaro 2010
31 Low T : a risk for prostate cancer Possible explanation: Prostate cancer exerts an inhibitory effect on Hypothalamic-Pituitary-Testicular-axis: T declines After RRP: T doubled in patients with G3! Miller, 1998 Madersbacher, 2002
32 Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there an association between T level and PCA-risk? What is the risk of PCA during TRT?
33 Evidence in support of an association between PCa and TRT No evidence of such correlation A trial of 6000 men randomized to receive testosterone or placebo for five years is necessary to determine if testosterone increases the incidence of prostate cancer by 30 percent
34 No significant effect of testosterone therapy on the incidence of prostatic cancer or the need for prostate biopsy ( Fernandez-Balsells, J Clin Endocrinol Metab 95: , 2010)
35 No difference in the risk of significant increase of PSA, changes in IPSS, LUTS and composite endpoints (Fernandez-Balsells, J Clin Endocrinol Metab 95: , 2010) Conclusions: these data do not support causality between Pca,LUTS and TRT
36 TRT and PCa TRT-treated men have no greater incidence of Ca prostate than non-treated men even in men at highest risk* The risk of developing prostate Ca on TRT is approx 1%, the same as non-trt treated population Rhoden E and Morgentaler A New England J Med 350: (2004) *Travis RC et al. Serum androgens and prostate cancer. Int J Cancer 2007:121: *Gann PH et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88: *American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients 2002 update. Endocr Pract. 2002;8(6):
37 Prostate cancer growth Proposed saturation model for the relation of PCa growth and serum T concentration Near castrate range Threshold beyond which T has no effect on growth of PCa Serum T levels Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am - 01-NOV-2007; 34(4): , vii
38 Molecular Basis for Saturation AR becomes maximally bound to androgen (saturated) at ~4 nmol/l (120 ng/dl) Morgentaler A, Traish AM Eur Urol 2009; 55: 310
39 Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there an association between T level and PCA-risk? What is the risk of PCA during TRT?
40 Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands
41
42 Fact All available evidence demonstrates a powerful effect of T on PCa growth at low T concentrations near castrate T concentrations BUT little or no effect of T on PCa growth above near castrate T concentrations
43 Fact Clinical evidence has demonstrated the possibility that the growth of androgen-independent prostate cancers might be reduced by the administration of androgens. Prehn RT Cancer Res 59: (1999)
44
45
46 Saturation model: the limits of androgen-dependent growth Khera, Sex Med Rev, 2013, vol 1 Morgentaler and Traish,2009
47 Do patients on TRT develop PCA? Is there a stimulation of latent PCA? Is there a de novo development of PCA? Answer: no: prevalence of PCA is similar to the general population: 1,1% Rhoden,J Urol,2003 Calof, 2005
48 Are serum sex steroid levels correlated with an increased risk of prostate events? Significance of all studies is limited because: 1) to establish linkage between development of a disease and certain steroid hormone levels, studies need to be prospective and should last until the disease of interest has developed; 2) circulating hormone levels vary significantly throughout the day and over the years. It is difficult to determine to what extent the level of a hormone measured once, reflects a lifetime index of hormone status; 3) the levels of circulating steroid hormones do not necessarily reflect their intraprostatic concentrations.
49 Does TRT induce prostate diseases? No evidence based on available data. However for conclusive evidence adequately powered prospective studies are needed Endocrine Society Guidelines: A patient on TRT obtain urological consultation if there is: An increase in serum PSA concentration >1.4 ng/ml within any 12- month period of testosterone treatment. A PSA velocity of >0.4 ng/ml yr using the PSA level after 6 months of testosterone administration as the reference Detection of a prostatic abnormality on digital rectal examination. An AUA/ IPSS prostate symptom score of >19 Bhasin S, J Clin Endocrinol Metab, June 2010, 95(6):
50 Low T :a risk for prostate cancer -Low T related to higher risk of PCA-progression -PSA/FT ratio: preop marker for G and T-stadium: if PSA/FT 0,40 : T3,T4 and G8 and G9! Garcia-Gruz, 2012 Porcaro,2010
Testosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands
Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone
More informationTESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?
TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of
More informationPRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationTRT and localized protate cancer
TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be
More informationTobias S. Kohler, MD, MPH, FACS Southern Illinois University School of Medicine AUA SMSNA Program May 7, 2016
Tobias S. Kohler, MD, MPH, FACS Southern Illinois University School of Medicine AUA SMSNA Program May 7, 2016 Abbvie Researcher/Consultant/Grant Funding Boston Scientific Researcher/Consultant/Grant Funding
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Hypogonadism: Treatment Safety and Prostate Health 2 Monitoring for Testosterone Therapy DRE 1,2 PSA Parameter Voiding/IPSS 1,2 Hemoglobin
More informationCan men on AS be treated with testosterone?
Can men on AS be treated with testosterone? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Conflicts of interest PI or member steering
More informationHow to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
More informationThe reality of LOH-symptoms
The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands The reality of LOH symptoms male external & internal genitalia Testosterone
More informationHYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)
HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION
More informationSignificance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
www.kjurology.org DOI:10.111/kju.010.51.1.81 Urological Oncology Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA
More informationPCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
More informationTHINGS ARE NOT ALWAYS AS THEY APPEAR. Assume Nothing!
THINGS ARE NOT ALWAYS AS THEY APPEAR Assume Nothing! UP SIDE DOWN WORLD OF PROSTATE CANCER Paul D. Thompson, M.D. Fort Worth Texas WHAT WE THOUGHT WE KNEW AND WHAT WE KNOW TODAY FINANCIAL DISCLOSURES
More informationEVIDENCE SUPPORTING TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER
EVIDENCE SUPPORTING TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER Abraham Morgentaler, MD Director and Founder Men s Health Boston Associate Clinical Professor Harvard Medical School And the Urology
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationOutcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
ORIGINAL ARTICLE Vol. 41 (6): 1167-1171, November. December, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0528 Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy
More informationTestosterone Substitution and the Prostate
European Urology Supplements European Urology Supplements 4 (2005) 16 23 Testosterone Substitution and the Prostate E. David Crawford* University of Colorado Health Sciences Center, 1665 N. Ursula Street,
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationTestosterone: Current Opinion and Controversy
Testosterone: Current Opinion and Controversy Ravi Kacker, MD Metrowest Urology (508) 655 4422 Medical Office Building at Leonard Morse Hospital Disclosures MHB Labs President and CEO of Drug Development
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationAn Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationresponse of PCa to testosterone deprivation in the early 1940s, testosterone has been considered as fuel to the fire of PCa.
BJUI BJU INTERNATIONAL Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment Eduardo Garc í a-cruz, Marta Piqueras, Jorge Huguet, Lluis Peri, Laura
More informationTestosterone Replacement Therapy and Prostate Cancer Incidence
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2015 December 33(3): 125-129 http://dx.doi.org/10.5534/wjmh.2015.33.3.125 Review Article Testosterone Replacement Therapy and Prostate Cancer Incidence
More informationTestosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd.
4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant
More informationTestosterone therapy and cancer risk
Sexual Medicine Testosterone therapy and cancer risk Michael L. Eisenberg*, Shufeng Li*, Paul Betts, Danielle Herder, Dolores J. Lamb and Larry I. Lipshultz Departments of *Urology, Obstetrics/Gynecology
More informationTake-Home Messages: Androgens
Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical
More informationHormone Replacement Therapy
Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone Oral Buccal Nasal Description
More informationManaging Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationCORRELATION BETWEEN SERUM TESTOSTE- RONE, BIOCHEMICAL AND CLINICAL MARKERS IN PROSTATE CANCER PATIENTS
Journal of IMAB ISSN: 1312-773X http://www.journal-imab-bg.org http://dx.doi.org/10.5272/jimab.2016223.1314 Journal of IMAB - Annual Proceeding (Scientific Papers) 2016, vol. 22, issue 3 CORRELATION BETWEEN
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: June 24, 2016 Testosterone Oral Buccal Nasal Description
More informationAlvaro Morales Centre for Applied Urological Research, Queen s University, Kingston, ON, Canada
. 11 Mini Reviews UNPREDICTABILITY OF TESTOSTERONE THERAPY MORALES BJUI Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry
More informationDiagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ)
Diagnosis and management of testosterone deficiency syndrome in adult men: clinical practice guideline (CMAJ) Alvaro Morales CM MD, Richard A. Bebb MD, Priya Manjoo MD MSc, Peter Assimakopoulos MD, John
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: December 8, 2017 Testosterone
More informationGUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde
GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely
More informationHow to detect and investigate Prostate Cancer before TRT
How to detect and investigate Prostate Cancer before TRT Frans M.J. Debruyne Professor of Urology Andros Men s Health Institutes, The Netherlands Bruges, 25-26 September 2014 PRISM Recommendations for
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
More informationHypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationTestosterone Oral Buccal Nasal. Android, Androxy, Methitest, Natesto, Striant, Testred. Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.32 Subject: Testosterone Oral Buccal Nasal Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone Oral Buccal Nasal
More informationWhat Is the Low T Syndrome? Is Testosterone Supplementation Safe?
What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or
More informationTestosterone Injection / Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Testosterone Injection / Implant Page: 1 of 9 Last Review Date: December 5, 2014 Testosterone
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationTestosterone Injection and Implant
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: November 30, 2018 Testosterone
More informationTestosterone Therapy in Men with Hypogonadism
Testosterone Therapy in Men with Hypogonadism (Endocrine Society 2018 Guideline) Ngwe Yin, MD Assistant Clinical Professor of Medicine, UCSF Fresno Medical Education Program Disclosures None Objective
More informationThe Clinical Potential of Pretreatment Serum Testosterone Level to Improve the Efficiency of Prostate Cancer Screening
european urology 51 (2007) 375 380 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Clinical Potential of Pretreatment Serum Testosterone Level to Improve
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.37 Subject: Testosterone Powder Page: 1 of 12 Last Review Date: November 30, 2018 Testosterone powder
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationBest Practices to Improve Patient Outcomes
Best Practices Pearls Practical Primary Care Strategies for Diagnosing and Managing Hypogonadism in Men Utilize lab testing in appropriate patients who have complaints consistent with the often subtle
More informationMODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT
MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT KEYWORDS: Prostate cancer, PSA, Screening, Radical Prostatectomy LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to:
More informationA dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male
Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.
More informationClinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:
Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More information6/14/2010. GnRH=Gonadotropin-Releasing Hormone.
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
More informationAn Update on Men s Health and Sexual Function
An Update on Men s Health and Sexual Function Lawrence Jenkins, MD, MBA Assistant Professor Clinical Department of Urology The Ohio State University Wexner Medical Center Outline Testosterone Deficiency
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationNaviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes
Naviga2ng the Adverse Effects of ADT: Improving Pa2ent Outcomes E. David Crawford, M.D. Professor of Surgery/ Urology/ Radiation Oncology University of Colorado Greetings from Colorado Disclosures Consultant:
More informationMedical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?
ORIGINAL PAPER DOI: 10.4081/aiua.2017.4.282 Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels? Murat Bagcioglu
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationSerum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study
european urology 51 (2007) 1645 1653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia Serum Prostate-Specific Antigen as a Predictor of Prostate
More informationLate onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
More informationIpogonadismo e carcinoma prostatico quando si può trattare con testosterone?
Ipogonadismo e carcinoma prostatico quando si può trattare con testosterone? FABIO LANFRANCO S.S. Andrologia, Seminologia, Crioconservazione, Disforia di Genere S.C.D.U. ENDOCRINOLOGIA, DIABETOLOGIA E
More informationRisk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA
Risk of renal side effects with ADT E. David Crawford University of Colorado, Aurora, CO, USA ADT: A key treatment for advanced prostate cancer John Hunter 1780-castration 1904: First RP 1938: Acid Phos.
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationHypogonadism in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Hypogonadism in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More information"To Replace or Not to Replace, that is the Question"
"To Replace or Not to Replace, that is the Question" Timothy Bailey, MD, FACE, CPI Director, AMCR Institute Clinical Associate Professor, UCSD School of Medicine Disclosures Research: Abbott, Ascensia,
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationHow do I control (monitor) patients receiving TRT after prostate cancer treatment
How do I control (monitor) patients receiving TRT after prostate cancer treatment Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery
More informationTestosterone (cypionate, enanthate, and propionate) powder, Fluoxymesterone powder, Methyltestosterone powder
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.37 Subject: Testosterone Powder Page: 1 of 11 Last Review Date: September 18, 2015 Testosterone powder
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationPCa Commentary. Volume 79 May June 2014
1221 Madison Street, 1 st Floor Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 79 May June 2014 CONTENT: Active Surveillance Page 1 Firmagon and Lupron Page 5 ACTIVE SURVEILLANCE:
More informationSaving. Kidneys. Prostate Cancer
Saving Kidneys 10 Prostate Cancer This booklet will tell you more about the prostate cancer. It will also help you understand this disease in a better way. You will also come to know the causes and treatment
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pellet (Testopel) Reference Number: CP.PHAR.354 Effective Date: 08.01.17 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the
More informationEFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE
EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationAvailable for Public Disclosure Without Redaction
PROSCAR (finasteride 5 mg) Supplemental New Drug Application Prostate Cancer Prevention Trial Oncologic Drugs Advisory Committee Briefing Document Presented to ODAC on 01-December 2010 Available for Public
More informationProf Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA
Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy
More informationQuality of Life with an Aging Prostate: The Sperling Prostate Center Protocol. Dan Sperling, MD, DABR The Sperling Prostate Center Delray Beach, FL
Quality of Life with an Aging Prostate: The Sperling Prostate Center Protocol Dan Sperling, MD, DABR The Sperling Prostate Center Delray Beach, FL As men age, physiological changes affect QOL Testosterone
More informationManipulating Hormones: Androgen Suppression in Prostate Cancer Patients
Focus on CME at the University of Queen s ManitobaUniversity Manipulating Hormones: Androgen Suppression in ostate Cancer Patients By D. Robert Siemens, MD, FRCSC Case A 62-year old man presents with complaints
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationThe Effect of Androgen-replacement Therapy on Prostate Growth: A Systematic Review and Meta-analysis
EUROPEAN UROLOGY 64 (2013) 811 822 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Benign Prostatic Enlargement The Effect of Androgen-replacement Therapy on Prostate
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationOutline. Classic Androgen deficiency. Cardiovascular Risk and Testosterone Fact vs Fiction. Professor Robert I McLachlan AM, FRACP, PhD
Health Ed Brisbane Saturday 27 th October 2018 Cardiovascular Risk and Testosterone Fact vs Fiction Professor Robert I McLachlan AM, FRACP, PhD Hudson Institute of Medical Research, Monash University Department
More informationRole of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia
[Medicine Update (2003): 11(2), 55-58] Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia Arora, R.P., CMO, Rajiba L.
More informationTestosterone Treatment: Myths Vs Reality. Fadi Al-Khayer, M.D, F.A.C.E
Testosterone Treatment: Myths Vs Reality Fadi Al-Khayer, M.D, F.A.C.E The Biological Functions of Testosterone in Men Testosterone is essential to the musculoskeletal and metabolic systems throughout a
More informationProstate Cancer Case Study 2. Medical Student Case-Based Learning
Prostate Cancer Case Study 2 Medical Student Case-Based Learning The Case of Mr. Powers Prostate Cancer Recurrence Mr. Powers is a young appearing, healthy 73-year old male who underwent a radical prostatectomy
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More information